• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ISPR

    Ispire Technology Inc.

    Subscribe to $ISPR
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    IPO Year: 2023

    Exchange: NASDAQ

    Recent Analyst Ratings for Ispire Technology Inc.

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    See more ratings

    Ispire Technology Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Technology Inc. Reports Financial Results for the Fiscal Year 2025

    LOS ANGELES, Sept. 16, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal year 2025, which ended on June 30, 2025. Fiscal Year 2025 Financial Results Revenue decreased to $127.5 million, compared to $151.9 million in the 2024 fiscal year.Gross profit declined to $22.6 million, as compared to $29.8 million in the 2024 fiscal year.Gross margin decreased to 17.8%, as compared to 19.6% in the 2024 fiscal year.Total operating expenses

    9/16/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Fourth Quarter and Full Year 2025 Earnings Conference Call

    LOS ANGELES, Sept. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") ((ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Tuesday, September 16, 2025, to discuss the Company's financial results for its fiscal fourth quarter and full year ended June 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Tuesday, September 16, 2025Time: 8:00am ETDial

    9/12/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Malaysia Reaffirms Full Regulatory Compliance and Export-Only Manufacturing Operations

    LOS ANGELES, June 9, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that its Malaysian subsidiary, Ispire Malaysia Sdn Bhd ("Ispire Malaysia"), reaffirmed its strict compliance with all applicable Malaysian laws and regulations. This clarification follows recent media reports and public interest concerning the Company's manufacturing activities in Malaysia. Ispire Malaysia confirms that all manufacturing activities at its facility in Johor are exclusively for export purposes and do not involve the production or distribution of any nicotine- or cannabis-containing liquids or gels within

    6/9/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire to Participate in the Benzinga Cannabis Capital Conference in Chicago on Tuesday, June 10, 2025

    Conference Attendance Follows Historic, First-Ever FDA Acceptance Review of a Standalone, Blockchain-Enabled Age-Gating System LOS ANGELES, June 6, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that the Company will participate in the Benzinga Cannabis Capital Conference, taking place from June 10-11, 2025, at the Marriott Magnificent Mile in Chicago, Illinois. Dennis Lider, SVP of Cannabis, will join the panel titled "The Hidden Winners in Cannabis: Profitable Businesses Without the Red Tape" on Tuesday, June 10, 2025, from 11:00 am to 11:30 am CDT on the Main Stage - Floor 5 (Chicag

    6/6/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire-Backed IKE Tech to Present 7th Annual Next Generation Nicotine Delivery USA Conference

    Conference Attendance Follows Groundbreaking FDA PMTA Filing for Blockchain-Powered Age-Gating System LOS ANGELES, June 3, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC ("IKE Tech"), a joint venture that includes Ispire as a founding partner, will showcase their technology at the 7th Annual Next Generation Nicotine Delivery USA at the Hyatt Regency in Miami from June 4-5th. This event convenes key business leaders from the FDA, the ENDS (Electronic Nicotine Delivery Systems) sector, and the tobacco industry across the U.S. market to explore strategies for legal compli

    6/3/25 8:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Approval of Interim License for Manufacturing of Nicotine Products in Malaysia

    Interim License Approved in May, with Authority to Begin Manufacturing of Nicotine Products in Malaysia Immediately LOS ANGELES, May 22, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced it has received the interim license from the Malaysian Government for the manufacturing of nicotine products. This is the first and only nicotine manufacturing license issued in Malaysia approved by both the Federal and State authorities and cements Ispire's position as the only company with full authorization for export, import, and production. The approval of the interim license

    5/22/25 9:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

    Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial PositionPost-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKELaunched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety  LOS ANGELES, May 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025. Fiscal Third Quarter 2025 Financial Results Revenue of $26.2 million versus $30.0 mil

    5/12/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technologies Inc. Schedules Fiscal Third Quarter 2025 Earnings Conference Call

    LOS ANGELAS, May 7, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Monday, May 12, 2025, to discuss the Company's financial results for the fiscal third quarter ended March 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Monday, May 12, 2025Time: 8:00am ETDial-In Numbers: North America 888-880-3330 or International +1 646-357-8766This conference call will be webcast live and can be accessed by all

    5/7/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CLO and Secretary Pryzbyla Steven P. sold $45,001 worth of shares (17,046 units at $2.64), decreasing direct ownership by 4% to 399,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    10/2/25 4:30:03 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Cox Brent was granted 29,784 shares, increasing direct ownership by 142% to 50,782 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    7/11/25 4:31:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Burch Christopher Robert was granted 27,178 shares, increasing direct ownership by 188% to 41,658 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    7/11/25 4:30:47 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Fargis John was granted 27,178 shares, increasing direct ownership by 140% to 46,599 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    7/11/25 4:30:24 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Yu Jay

    3 - Ispire Technology Inc. (0001948455) (Issuer)

    6/20/25 4:30:03 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    CLO and Secretary Pryzbyla Steven P. sold $1,785 worth of shares (500 units at $3.57), decreasing direct ownership by 0.12% to 416,710 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/19/25 4:30:15 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    CLO and Secretary Pryzbyla Steven P. sold $24,982 worth of shares (6,200 units at $4.03), decreasing direct ownership by 1% to 417,210 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/14/25 4:30:05 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Cox Brent was granted 8,077 shares, increasing direct ownership by 63% to 20,998 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    1/10/25 6:05:19 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Burch Christopher Robert was granted 7,370 shares, increasing direct ownership by 104% to 14,480 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    1/10/25 6:04:15 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Fargis John was granted 7,370 shares, increasing direct ownership by 61% to 19,421 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    1/10/25 6:03:20 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. SEC Filings

    View All

    Ispire Technology Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    6/26/25 4:30:08 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    5/23/25 4:30:34 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    5/15/25 4:30:11 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    5/12/25 7:00:13 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    5/9/25 4:30:50 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Leadership Update

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    2/28/25 5:00:09 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    2/21/25 5:00:36 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    2/14/25 4:30:19 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    2/10/25 7:00:53 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Leadership Updates

    Live Leadership Updates

    View All

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Key Leadership Appointments

    LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or "the Company") (NASDAQ:ISPR), a leader in vapor technology, providing high-quality, innovative products with first-class performance, announced today the appointment of Michael Wang as its Co-Chief Executive Officer.  Mr. Wang previously served as Chief Financial Officer. Concurrently, Daniel J. Machock was appointed as the new Chief Financial Officer. Mr. Wang has assumed the role of Co-Chief Executive Officer alongside Tuanfang Liu, as Co-Chief Executive Officer. This strengthened leadership structure is designed to refine Ispire's strategic direction and spearhead the Company's future growth. Ispire's decision

    8/14/23 8:35:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for the Fiscal Year 2025

    LOS ANGELES, Sept. 16, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal year 2025, which ended on June 30, 2025. Fiscal Year 2025 Financial Results Revenue decreased to $127.5 million, compared to $151.9 million in the 2024 fiscal year.Gross profit declined to $22.6 million, as compared to $29.8 million in the 2024 fiscal year.Gross margin decreased to 17.8%, as compared to 19.6% in the 2024 fiscal year.Total operating expenses

    9/16/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Fourth Quarter and Full Year 2025 Earnings Conference Call

    LOS ANGELES, Sept. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") ((ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Tuesday, September 16, 2025, to discuss the Company's financial results for its fiscal fourth quarter and full year ended June 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Tuesday, September 16, 2025Time: 8:00am ETDial

    9/12/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

    Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial PositionPost-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKELaunched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety  LOS ANGELES, May 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025. Fiscal Third Quarter 2025 Financial Results Revenue of $26.2 million versus $30.0 mil

    5/12/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technologies Inc. Schedules Fiscal Third Quarter 2025 Earnings Conference Call

    LOS ANGELAS, May 7, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Monday, May 12, 2025, to discuss the Company's financial results for the fiscal third quarter ended March 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Monday, May 12, 2025Time: 8:00am ETDial-In Numbers: North America 888-880-3330 or International +1 646-357-8766This conference call will be webcast live and can be accessed by all

    5/7/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. to Participate in Webull Corporate Webinar Series on February 18, 2025

    LOS ANGELES, Feb. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced that Michael Wang, Co-Chief Executive Officer, will present at the Webull Consumer Webinar Series: Consumer, on February 18, 2025. Conference Details: Webull Corporate Webinar Series - ConsumerDate/Time: Tuesday, February 18th at approximately 3:00 p.m. ETPresenter: Michael Wang, Co-CEORegistration Link: HERERecent Highlights: 2/10/25: Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2025 1/22/25: Ispire Technology Inc. Announces Stock Repurchase Program 1/15/25: Ispi

    2/12/25 8:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2025

    Gross Profit Increased 23.5% from the Previous Year to $7.7 million Gross Margins Increased to 18.5%, up from 15.0% the Previous Year Revenue Increased 0.3% Year-Over-Year to $41.8 Million LOS ANGELES, Feb. 10, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal second quarter 2025, which ended on December 31, 2024. Fiscal Second Quarter 2025 Financial Results Revenue of $41.8 million, compared to $41.7 million for the fiscal second quarter of 2024.Gross profit of $7.7 million, an increase of 23.5% compared to $6.3 million in the fiscal second

    2/10/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Second Quarter 2025 Earnings Conference Call

    LOS ANGELES, Feb. 4, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Monday, February 10, 2025, to discuss the Company's financial results for its fiscal second quarter ended December 31, 2024. To attend the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Monday, February 10, 2025Time: 8:00am ETDial-In Numbers: United States 877-451-6152 or International +1 201-389-0879This conference call will be broadcast live on the Intern

    2/4/25 5:00:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Reports Financial Results for Fiscal First Quarter 2025

    Gross Profit Increased 13.2% Year-Over-Year to $7.7 Million Gross Margins increased to 19.5%, up from 16.0% in Fiscal Q1 2024 Expanded Global Reach through 5-Year Master Distributor Agreement with ANDS for MENA and Global Duty-Free Markets LOS ANGELES, Nov. 11, 2024 /PRNewswire/ --  Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal first quarter 2025, which ended on September 30, 2024, and anticipates filing its annual report on Form 10-Q with the U.S. Securities and Exchange Commission (the "SEC") on November 12, 2024. Fiscal First Quarter 2025 Financial Results

    11/11/24 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    /C O R R E C T I O N -- Ispire Technology Inc./

    In the news release, Ispire Technologies Inc. Schedules Fiscal First Quarter 2025 Earnings Conference Call, issued 07-Nov-2024 by Ispire Technology Inc. over PR Newswire, we are advised by the company that the date of the conference call should read "Monday, November 11, 2024", rather than "Tuesday, November 12, 2024", and the dial-In numbers should be "United States 844-826-3033 or International +1 412-317-5185" rather than as originally issued inadvertently. The complete, corrected release follows: Ispire Technologies Inc. Schedules Fiscal First Quarter 2025 Earnings Conference Call LOS ANGELES, Nov. 7, 2024 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR

    11/7/24 8:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technologies Inc. Schedules Fiscal First Quarter 2025 Earnings Conference Call

    LOS ANGELES, Nov. 7, 2024 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), an innovator in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Tuesday, November 12, 2024, to discuss the Company's financial results for its fiscal first quarter ended September 30, 2024. To attend the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Tuesday, November 12, 2024Time: 8:00am ETDial-In Numbers: United States 866-250-8117 or International +1 412-317-6011This conference call will be broadcast live on the Inter

    11/7/24 8:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care